Eli Lilly (NY:LLY)

1,142.85 -7.00 (-0.61%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗

August 21, 2026

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Via The Motley Fool

Topics ETFs

Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 5 Years ↗

August 21, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.41% on an annualized basis producing an average annual return of 36.72%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Stock Split Watch: Is Eli Lilly (LLY) Stock Next? ↗

August 21, 2026

Shares recently traded at $1,280 each, so a split wouldn't be surprising.

Via The Motley Fool

Eli Lilly (NYSE:LLY) Shows Strong Growth and a Compelling Technical Setup ↗

August 21, 2026

Via Chartmill

In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech? ↗

August 20, 2026

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

Via The Motley Fool

Topics ETFs

There’s a Black Market for Eli Lilly’s Unapproved GLP-1 Drug. Here’s Why That’s Bullish ↗

August 20, 2026

Can anyone challenge Eli Lilly in the weight loss space?

Via The Motley Fool

Topics Intellectual Property Lawsuit

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy? ↗

August 20, 2026

XBI is up nearly 80% over the past year, but has experienced a much larger maximum drawdown over the past five years. IHE has delivered steadier returns and offers a higher dividend yield.

Via The Motley Fool

Topics ETFs

Could Eli Lilly Be Worth More Than SpaceX by the End of 2026? ↗

August 19, 2026

These two stocks both have market caps of more than $1 trillion, but Eli Lilly's valuation is supported by strong financials.

Via The Motley Fool

Absci (ABSI) Q2 2026 Earnings Call Transcript ↗

August 19, 2026

Biotech extends runway to 2028 with $100M financing and Eli Lilly deal.

Via The Motley Fool

Topics Earnings

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

News Provided by USA News Group on behalf of MindWalk Holdings Corp.

From USA News Group

Via GlobeNewswire

Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market ↗

August 19, 2026

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion obesity market.

Via Investor's Business Daily

Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’ ↗

August 19, 2026

Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.

Via Benzinga

Why Eli Lilly (LLY) Stock Is Up Today

August 18, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...

Via StockStory

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.

August 18, 2026

From Equity Insider

Via GlobeNewswire

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

U.S. Physical Therapy Names Nchacha Etta as Chief Financial Officer /www.snipeso ↗

August 18, 2026

Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana

Via Talk Markets

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

August 18, 2026

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Via The Motley Fool

If I Were in My 20s, I'd Buy This Unstoppable Vanguard ETF and Hold It Forever ↗

August 18, 2026

Investors can reap big rewards over the long term by betting on growth in their younger years.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum

August 17, 2026

Via AB Newswire

Topics Animal Testing Artificial Intelligence

Why Is Omniab Stock Rallying After Eli Lilly Deal? ↗

August 17, 2026

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket

Via Benzinga

Wall Street Says the Stock Market's Return Will Crush the Long-Term Average in the Next Year ↗

August 17, 2026

The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.

Via The Motley Fool

Topics Stocks

1 of Wall Street’s Favorite Stocks on Our Watchlist and 2 We Find Risky

August 17, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient ↗

August 15, 2026

The company's peers in the pharmaceutical industry should be worried.

Via The Motley Fool

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗

August 14, 2026

They are way more than just GLP-1 stocks.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗

August 14, 2026

The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.

Via The Motley Fool

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗

August 14, 2026

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Via The Motley Fool

Topics ETFs

Amphastar (AMPH) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

New product launches drove 5% revenue growth and margin expansion.

Via The Motley Fool

Topics Earnings

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗

August 13, 2026

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.